What Giapreza Treats: Main Uses and Benefits

Giapreza is used in critical care settings to address critically low blood pressure (hypotension) associated with distributive shock, such as septic shock. It is indicated for use when a patient's low blood pressure remains insufficient after the use of initial supportive therapies. The primary applications for this medication include managing refractory hypotension, addressing symptoms associated with low systemic vascular resistance, and supporting functional stability during an acute crisis. This supports the patient during episodes requiring the stabilization of circulation and assists with maintaining essential blood pressure levels.

“This supportive therapeutic approach helps to ease the overall symptom load and supports the patient during difficult episodes of shock.”

By helping to support the pressure needed for adequate blood flow (perfusion) to vital organs, the medication may help with reducing the risk of functional stress associated with prolonged, critically low pressure. This assists with maintaining functional stability and is considered relevant for providing assistance during these acute episodes.

Quick Fact: Relief for Refractory Low Blood Pressure

Regulatory References

1. European Medicines Agency overview

Who can and cannot use Giapreza?

The official regulatory documents strictly define the patient population eligible for Giapreza (angiotensin II) and impose specific limitations for use.

Eligibility Scope

Special Population Rules

• Pregnancy: Use should be avoided if possible. However, in this emergency setting, delaying treatment for hypotension associated with shock may increase maternal and fetal risk.
• Lactation: Breast-feeding must be discontinued during treatment with Giapreza.
• Other Types of Shock: The medicine is not recommended for use in non-distributive shocks (e.g., cardiogenic shock) because these patient populations were excluded from clinical trials.
• Geriatric Use: Use in patients 65 years and older showed no significant difference in safety or efficacy compared to younger adults; no special dose adjustment is required.

The overall regulatory structure limits the medicine’s use to a narrow, critical adult population who meet specific criteria, while formally excluding use in cases of known hypersensitivity or when necessary VTE prophylaxis cannot be administered.

Giapreza’s interaction profile, as defined by official regulatory documents, is predominantly characterized by pharmacodynamic effects related to its role as an Angiotensin II Agonist. The official labeling identifies three main categories of interacting medicines, focusing on altered blood pressure responses rather than metabolic clearance.

Co-administration with other vasopressor agents, such as norepinephrine or vasopressin, may result in an additive effect on mean arterial pressure (MAP). This requires clinical consideration of the doses of concomitant pressors. Furthermore, Giapreza’s pressor effect can be modified by medicines that affect the Renin-Angiotensin System (RAS).

• Patients who have recently received Angiotensin Converting Enzyme (ACE) inhibitors may exhibit increased sensitivity and an elevated pressor response to Giapreza.
• Patients who have recently received Angiotensin II Receptor Blockers (ARBs) may show reduced sensitivity and a blunted pressor response.

Crucially, official regulatory documents state that there are no formal contraindications listed for Giapreza. The drug's interaction profile does not include documentation of metabolic interactions, as formal studies regarding Cytochrome P450 (CYP) enzyme inhibition or induction have not been performed. The regulatory documents also do not specify any mandatory timing-based separation rules or documented interactions with food, alcohol, or herbal products.

Giapreza is a synthetic human angiotensin II peptide, a primary effector hormone of the renin-angiotensin-aldosterone system (RAAS). The molecule functions as an agonist, binding directly to the G-protein-coupled angiotensin II receptor type 1 ( AT1) expressed on vascular smooth muscle cells (VSMCs) throughout the systemic circulation. This interaction activates the Gq protein, which initiates an intracellular signaling cascade involving phospholipase C beta ( PLCbeta), inositol triphosphate ( IP3), and subsequent release of calcium ions ( Ca^2+) from the sarcoplasmic reticulum. The increase in intracellular Ca^2+ concentration facilitates the calmodulin-dependent phosphorylation of myosin, leading directly to the contraction of the vascular smooth muscle fibers. This widespread vasoconstriction increases systemic vascular resistance (SVR). Concurrently, angiotensin II stimulates the adrenal cortex, primarily the zona glomerulosa, to secrete aldosterone, and acts on the proximal renal tubules to modulate Na^+ and water reabsorption. The combined effect of increased SVR and fluid-retaining hormonal activity results in system-level modulation of arterial pressure.

Official Administration Guidelines

Giapreza (Angiotensin II) is provided as a concentrate that must be administered as a continuous intravenous infusion in an acute, closely monitored hospital setting. Its administration follows a specific, protocol-driven sequence.

Administration Scope

Labeled Dosing and Schedule

The dosage is highly specific and requires frequent adjustment based on the patient's blood pressure response:

• Recommended Starting Dose: 20 nanograms (ng)/kg/min.
• Titration Frequency: Doses may be adjusted (titrated) as frequently as every 5 minutes by increments up to 15 ng/kg/min.
• Maximum Dose (First 3 Hours): The dose must not exceed 80 ng/kg/min during the initial three hours of treatment.
• Maintenance Dose: The maximum dose should not exceed 40 ng/kg/min.
• Tapering: Upon discontinuation, the dose must be down-titrated gradually by decrements of up to 15 ng/kg/min every 5 to 15 minutes to prevent abrupt changes in blood pressure.

For specific patient populations, no special dose adjustment is required for older adults (over 75 years) or patients with renal or hepatic impairment. The safety and efficacy of Giapreza in children under 18 years old have not been established.

Evidence for Use in Refractory Distributive Shock

This section will summarize the structure of the clinical research, focusing on the key randomized controlled trials (RCTs) and systematic reviews that evaluated the use of Angiotensin II in adult patients with critically low blood pressure, or refractory distributive shock.

The core research was conducted during periods of increased symptom activity in adults who had distributive shock, a condition associated with acute or disruptive episodes. This research examined temporary physiological imbalance in patients whose blood pressure remained low despite already receiving standard-of-care vasopressor medications.

Outcomes Evaluated in Primary Trials

Studies monitored outcomes related to systemic or functional imbalance. The main goal researchers focused on was the proportion of patients achieving a target blood pressure (Mean Arterial Pressure, or MAP) threshold. This research explored short-term symptom changes by measuring this response within the first three hours after treatment was started. Additionally, studies examined the amount of concurrent standard vasopressor dose required by patients. Patterns of blood pressure response were described in the groups that received Angiotensin II, in contrast to the placebo group.

Examining Longer-Term Clinical Outcomes and Follow-up

Research explored outcomes reflecting daily functioning or activity level in the observed populations. While the primary goal of the main study involved the short-term goal of stabilizing blood pressure, studies monitored patient status for a longer duration to gather additional data.

Studies on Survival and Extended Observation

Research described the incidence of 28-day all-cause mortality as one of the secondary outcomes related to physical discomfort. However, it is not yet clear whether a definite impact on this longer-term endpoint exists, as the study sample sizes were modest. The follow-up durations were limited to 28 days for this specific measurement.

Research in Special and Vulnerable Patient Populations

Evidence Gaps for Certain Patient Groups

Research so far indicates that data for certain groups remain insufficient. For instance, there is a lack of available research data for pediatric patients (children and adolescents), as this population was not included in the primary clinical trials. Evidence remains limited regarding patterns in other specific subgroups of critically ill patients.

Understanding the Key Limitations and Areas of Uncertainty

The main research that supported regulatory review focused on outcomes describing episodic or acute changes; consequently, long-term effects are not fully established. The primary endpoint was observed in a short period (3 hours), which provides limited insight into long-term patient stability. This research provides context but not individual predictions about how any single patient may respond.

Key Studies & References

1. Angiotensin II for the Treatment of High-Output Shock 3 (ATHOS-3): protocol for a phase III, double-blind, randomised controlled trial

Common questions about Giapreza (FAQ)

Q: How long does Giapreza typically stay in the patient's system?

According to official product information, the medicine acts very quickly, and its presence in the bloodstream is short-lived. The plasma half-life, which is the time it takes for the concentration of the medicine in the blood to decrease by half, is described in official documents as being less than one minute.

Q: Can Giapreza cause issues with high heart rate (tachycardia)?

Official safety summaries list tachycardia (an abnormally high heart rate) as a common adverse reaction reported in clinical studies. This is a potential effect related to the medicine’s action on the vascular system, and for this reason, close hemodynamic monitoring is required during administration.

Q: How does Giapreza affect the use of other vasopressors a patient may be receiving?

Clinical studies indicated that the use of this medicine often reduced the doses of other vasopressors (blood pressure-raising medicines) that patients required to achieve their blood pressure goal. However, co-administration with other vasopressor agents may have an additive effect on blood pressure.

Q: What does the clinical trial evidence say about the speed of response to Giapreza?

Evidence from the main clinical study showed that the median time for patients to achieve the target blood pressure goal was approximately 5 minutes after the start of treatment. This rapid observed response is consistent with its very short half-life in the body.

Q: What is the typical timeframe for a patient to be treated with Giapreza?

The medicine is generally administered for the acute phase until the underlying condition causing the shock is sufficiently improved. The duration of treatment is not fixed and is determined by the patient's underlying condition. Once treatment is no longer needed, the dosage is gradually down-titrated (lowered).

Q: Does Giapreza cause a rebound drop in blood pressure when it is discontinued?

Regulatory documents state that abrupt withdrawal (stopping suddenly) may lead to rebound hypotension or a worsening of the underlying condition. For this reason, official guidelines state that the dosage is gradually down-titrated under medical supervision.

Q: How does Giapreza compare to traditional vasopressors like norepinephrine?

Official documents describe the medicine as being distinct because it utilizes the Renin-Angiotensin-Aldosterone System (RAAS) pathway to raise blood pressure. This is a unique, non-catecholamine mechanism, differentiating it from traditional vasopressors such as norepinephrine that act via the sympathetic nervous system.

Q: Does Giapreza cause problems with high levels of potassium in the blood?

The medicine’s function through the RAAS system involves stimulating aldosterone, a hormone that helps regulate potassium and sodium balance. However, high potassium levels (hyperkalemia) are not listed as a common or very common adverse reaction in official safety summaries.

Q: What is the likelihood of needing Giapreza in a critical care setting?

Regulatory documents specify that the medicine is indicated for use in adult patients who are in shock and whose blood pressure remains critically low despite treatment with other vasopressors. Its authorized use is consistent with a role in more complex or refractory (resistant) cases of distributive shock.

Q: Is Giapreza the same thing as the body's natural angiotensin II?

The active substance in the medicine is a synthetic peptide that is identical in structure to the human hormone Angiotensin II. While manufactured, it is designed to mimic the natural hormone's function in the body.

Q: Does Giapreza work immediately when it is given?

Studies and official information indicate the medicine acts very rapidly. This is consistent with its very short half-life. Clinical trials showed that the median time to achieve the target blood pressure goal was approximately 5 minutes after starting the infusion.

Q: Are the side effects of Giapreza generally similar to other shock medicines?

Reviews by regulatory bodies, such as the European Medicines Agency, have noted that the side effects observed with this medicine were considered similar to those of standard treatments for shock. These effects were reported to be manageable under clinical supervision.

Q: Does the patient's diet or any food interact with Giapreza?

Regulatory documents state that formal studies regarding metabolic interactions with food, alcohol, or herbal products have not been performed. Therefore, there are no specified timing-based separation rules regarding food or diet in the official labeling.

Q: Is Giapreza ever used in children or pediatric patients?

The safety and effectiveness of this medicine in pediatric patients (children under 18 years old) have not been established in the clinical trials that supported regulatory approval. Its use is limited to the approved adult population.

Q: Was Giapreza shown to improve patient survival rates in the main studies?

Research examining longer-term outcomes showed no significant difference in the 28-day survival rates compared to the placebo group. The primary clinical study was specifically designed to measure blood pressure response, not overall survival.

Q: Why is Giapreza considered a catecholamine-sparing agent?

It is described as catecholamine-sparing because clinical studies showed that its use reduced the dose of other vasopressors (which are catecholamines) that patients required. This allows for lower reliance on the traditional vasopressors used in shock.

Q: Does Giapreza affect fluid balance in the body?

The medicine's action through the RAAS system affects fluid balance. It stimulates the release of aldosterone and modulates sodium and water reabsorption by the kidneys, which contributes to regulating fluid volume and blood pressure.

Q: Why is Angiotensin II a hormone that raises blood pressure?

Angiotensin II is a naturally occurring peptide hormone and a primary effector of the RAAS system. It raises blood pressure through two main actions: causing direct vasoconstriction (narrowing of blood vessels) and promoting the retention of sodium and water in the body.

Q: Why is Giapreza considered a 'novel' treatment for shock?

It is described as a novel treatment because it was the first medicine of its kind to be approved that directly uses the Renin-Angiotensin-Aldosterone System (RAAS) pathway to increase blood pressure in shock. This offered a unique mechanism compared to existing therapies.

Q: Does Giapreza affect the patient's heart rhythm?

Official safety information lists tachycardia (an increased heart rate) as a common adverse reaction reported in clinical studies. Close monitoring of the patient’s heart function and rhythm is required while the medicine is being administered.

How to Store and Dispose of Giapreza

Giapreza (angiotensin II) concentrate requires specific environmental controls as stated in regulatory labeling:

Unmixed Concentrate Storage

Stability and Disposal

Once the concentrate is diluted for infusion, the prepared solution must be discarded after 24 hours. This time limit applies whether the diluted product is stored at room temperature or refrigerated.

The vial and any unused portion must be discarded after use. Disposal of this medicinal waste must be carried out in accordance with local requirements for pharmaceutical waste, and not through standard household disposal.